Pfizer Inc. (NYSE:PFE) Stake Lifted by First Hawaiian Bank

First Hawaiian Bank increased its position in shares of Pfizer Inc. (NYSE:PFE) by 312.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,176 shares of the biopharmaceutical company’s stock after purchasing an additional 19,078 shares during the quarter. First Hawaiian Bank’s holdings in Pfizer were worth $914,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Wendell David Associates Inc. increased its stake in shares of Pfizer by 2.4% in the second quarter. Wendell David Associates Inc. now owns 57,613 shares of the biopharmaceutical company’s stock valued at $2,090,000 after buying an additional 1,363 shares during the period. Chesley Taft & Associates LLC increased its position in Pfizer by 0.7% during the 2nd quarter. Chesley Taft & Associates LLC now owns 221,682 shares of the biopharmaceutical company’s stock valued at $8,043,000 after purchasing an additional 1,432 shares during the period. Gamco Investors INC. ET AL increased its position in Pfizer by 0.4% during the 1st quarter. Gamco Investors INC. ET AL now owns 387,501 shares of the biopharmaceutical company’s stock valued at $13,752,000 after purchasing an additional 1,470 shares during the period. Quadrant Private Wealth Management LLC increased its position in Pfizer by 6.5% during the 1st quarter. Quadrant Private Wealth Management LLC now owns 24,376 shares of the biopharmaceutical company’s stock valued at $865,000 after purchasing an additional 1,494 shares during the period. Finally, Callahan Advisors LLC increased its position in Pfizer by 0.5% during the 1st quarter. Callahan Advisors LLC now owns 293,220 shares of the biopharmaceutical company’s stock valued at $10,406,000 after purchasing an additional 1,503 shares during the period. 68.95% of the stock is owned by institutional investors and hedge funds.

In related news, insider Alexander R. Mackenzie sold 25,642 shares of Pfizer stock in a transaction dated Friday, August 3rd. The stock was sold at an average price of $39.51, for a total value of $1,013,115.42. Following the completion of the sale, the insider now owns 127,954 shares of the company’s stock, valued at approximately $5,055,462.54. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the sale, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. Insiders have sold a total of 761,230 shares of company stock worth $29,054,690 over the last quarter. Company insiders own 0.06% of the company’s stock.

A number of analysts have weighed in on the stock. Independent Research set a $48.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Thursday. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday. Barclays reissued a “neutral” rating and set a $40.00 target price on shares of Pfizer in a research report on Wednesday, September 26th. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, October 1st. Finally, Morningstar set a $46.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Thursday, September 27th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have assigned a buy rating to the company. Pfizer has a consensus rating of “Hold” and a consensus target price of $42.40.

Shares of NYSE PFE traded up $0.37 during mid-day trading on Monday, reaching $45.28. 20,069,000 shares of the company’s stock were exchanged, compared to its average volume of 21,657,441. The stock has a market capitalization of $262.34 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 2.23 and a beta of 0.96. Pfizer Inc. has a 52 week low of $33.20 and a 52 week high of $45.32. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. The company had revenue of $13.47 billion for the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS. Research analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date is Thursday, November 8th. Pfizer’s payout ratio is 51.32%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: Understanding Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply